Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elan, a biotechnology company has entered into a manufacturing agreement with Lonza Group to supply active pharmaceutical ingredient for ELND005 (Scyllo-inositol).
Subscribe to our email newsletter
ELND005 is used in the treatment of neuropsychiatric disorders such as Alzheimer’s and bipolar.
The company plans to initiate a proof of concept, Phase II study in bipolar disorder.
Elan modified its Collaboration Agreement with Transition Therapeutics in December 2010, following which Transition exercised its opt-out right, and is not funding the development or commercialization of ELND005.
Transition also gave up its 30% ownership of ELND005 to Elan.